{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T11:58:26Z","timestamp":1791979106153,"version":"4.4.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"S4","license":[{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T00:00:00Z","timestamp":1777507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100009057","name":"University of Graz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009057","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Wien Klin Wochenschr"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title>\n                  <jats:p>In den letzten Jahren hat die bessere Verf\u00fcgbarkeit und Nutzung automatisierter Insulinabgabesysteme (AID) gezeigt, dass Menschen mit AID-Behandlung in h\u00f6herem Ausma\u00df glyk\u00e4mische Therapieziele erreichen und dass dies mit einer Verbesserung der Lebensqualit\u00e4t einhergeht. Regelm\u00e4\u00dfige physische Aktivit\u00e4t und Sport sind grundlegende Bestandteile der Diabetesbehandlung bei Menschen mit Diabetes mellitus Typ\u00a01 und verbessern neben der glyk\u00e4mischen Einstellung und der allgemeinen Gesundheit auch die Lebensqualit\u00e4t. Trotz der klaren Evidenz f\u00fcr die positiven Effekte von physischer Aktivit\u00e4t und Sport stellen Glukoseschwankungen w\u00e4hrend dieser Aktivit\u00e4ten eine Herausforderung f\u00fcr Menschen mit Diabetes und ihre Therapie dar. Die Zunahme an Evidenz \u00fcber die letzten Jahre mit vermehrt klinischen Studien und \u00dcbersichtsarbeiten zu verschiedenen AID-Systemen bei physischer Aktivit\u00e4t und Sport f\u00fchrte zur Erstellung eines gemeinsamen Positionspapiers zweier gro\u00dfer Diabetesgesellschaften, der Europ\u00e4ischen Diabetes Gesellschaft (EASD) und der Internationalen Gesellschaft f\u00fcr p\u00e4diatrischen und adoleszenten Diabetes (ISPAD). Dieses Positionspapier fasst die aktuelle Evidenz zu AID-Systemen zusammen und bietet praxisnahe Empfehlungen f\u00fcr das Management von physischer Aktivit\u00e4t und Sport bei Kindern, Jugendlichen und Erwachsenen mit Diabetes mellitus Typ\u00a01 unter Nutzung von AID-Systemen. Diese Arbeit bietet die Grundlage f\u00fcr die hier vorliegende deutschsprachige gemeinsame Leitlinie der Deutschen Diabetes Gesellschaft (DDG) und der \u00d6sterreichischen Diabetes Gesellschaft (\u00d6DG) zum Thema AID, physische Aktivit\u00e4t und Sport bei Diabetes mellitus Typ\u00a01. In dieser Leitlinie werden alle in Deutschland und \u00d6sterreich verf\u00fcgbaren AID-Systeme vorgestellt und systemspezifische Empfehlungen f\u00fcr deren Anwendung bei physischer Aktivit\u00e4t und Sport gegeben. Dar\u00fcber hinaus werden unterschiedliche Glukosereaktionen f\u00fcr physische Aktivit\u00e4t und Sport besprochen und differenzierte Therapieoptionen aufgezeigt, um Glukoseschwankungen zu vermeiden und den gew\u00fcnschten Glukosezielbereich zu erreichen.<\/jats:p>","DOI":"10.1007\/s00508-025-02663-y","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:12:28Z","timestamp":1779315148000},"page":"386-403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Automatisierte Insulinabgabesysteme (AID), physische Aktivit\u00e4t und Sport bei Diabetes mellitus Typ\u00a01: eine gemeinsame Leitlinie der DDG und \u00d6DG","Automated insulin delivery (AID) systems, physical activity and sports in type\u00a01 diabetes mellitus: joint guidelines of the DDG and \u00d6DG"],"prefix":"10.1007","volume":"138","author":[{"given":"Othmar","family":"Moser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Becker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louisa","family":"van den Boom","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Brinkmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Danne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elke","family":"Fr\u00f6hlich-Reiterer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Gehr","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonia-Therese","family":"Kietaibl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd","family":"K\u00f6hler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Kress","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia K.","family":"Mader","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit","family":"Rami-Merhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominik","family":"Pesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Sch\u00fctz-Fuhrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harald","family":"Sourij","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Tauschmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Thurm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerlies","family":"Treiber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabine","family":"Hofer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,30]]},"reference":[{"key":"2663_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1111\/pedi.13452","volume":"23","author":"P Adolfsson","year":"2022","unstructured":"Adolfsson\u00a0P, Taplin\u00a0CE, Zaharieva\u00a0DP, Pemberton\u00a0J, Davis\u00a0EA, Riddell\u00a0MC, et\u00a0al. ISPAD Clinical Practice Consensus Guidelines 2022: Exercise in children and adolescents with diabetes. Pediatr Diabetes. 2022;23:1341\u201372.","journal-title":"Pediatr Diabetes"},{"key":"2663_CR2","first-page":"1","volume":"8587","author":"MC Riddell","year":"2017","unstructured":"Riddell\u00a0MC, Gallen\u00a0IW, Smart\u00a0CE, Taplin\u00a0CE, Adolfsson\u00a0P, Lumb\u00a0AN, et\u00a0al. Exercise management in type\u00a01 diabetes: a\u00a0consensus statement. Lancet Diabetes Endocrinol. 2017;8587:1\u201314.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2663_CR3","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.2337\/dc16-1728","volume":"39","author":"SR Colberg","year":"2016","unstructured":"Colberg\u00a0SR, Sigal\u00a0RJ, Yardley\u00a0JE, Riddell\u00a0MC, Dunstan\u00a0DW, Dempsey\u00a0PC, et\u00a0al. Physical Activity\/Exercise and Diabetes: A\u00a0Position Statement of the American Diabetes Association. Diabetes Care. 2016;39:2065\u201379.","journal-title":"Diabetes Care"},{"key":"2663_CR4","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s00125-020-05263-9","volume":"63","author":"O Moser","year":"2020","unstructured":"Moser\u00a0O, Riddell\u00a0MC, Eckstein\u00a0ML, Adolfsson\u00a0P, Rabasa-Lhoret\u00a0R, van den Boom\u00a0L, et\u00a0al. Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type\u00a01 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society f. Diabetologia. 2020;63:2501\u201320.","journal-title":"Diabetologia"},{"key":"2663_CR5","doi-asserted-by":"crossref","unstructured":"Kramme J, Moser O, Heise T, Pesta D. Typ-1-Diabetes und Sport. Diabetes Aktuell. 2024. http:\/\/www.thieme-connect.com\/products\/ejournals\/html\/10.1055\/a-2245-3786. Zugegriffen: 17. Juni 2025.","DOI":"10.1055\/a-2245-3786"},{"key":"2663_CR6","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1210\/endrev\/bnac022","volume":"44","author":"M Phillip","year":"2023","unstructured":"Phillip\u00a0M, Nimri\u00a0R, Bergenstal\u00a0RM, Barnard-Kelly\u00a0K, Danne\u00a0T, Hovorka\u00a0R, et\u00a0al. Consensus Recommendations for the Use of Automated Insulin Delivery Technologies in Clinical Practice. Endocr Rev. 2023;44:254\u201380.","journal-title":"Endocr Rev"},{"key":"2663_CR7","doi-asserted-by":"publisher","first-page":"127","DOI":"10.2337\/dsi22-0018","volume":"36","author":"DP Zaharieva","year":"2023","unstructured":"Zaharieva\u00a0DP, Morrison\u00a0D, Paldus\u00a0B, Lal\u00a0RA, Buckingham\u00a0BA, O\u2019Neal\u00a0DN. Practical Aspects and Exercise Safety Benefits of Automated Insulin Delivery Systems in Type\u00a01 Diabetes. Diabetes Spectr. 2023;36:127\u201336.","journal-title":"Diabetes Spectr"},{"key":"2663_CR8","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1089\/dia.2023.0420","volume":"26","author":"DN O\u2019Neal","year":"2024","unstructured":"O\u2019Neal\u00a0DN, Zaharieva\u00a0DP, Morrison\u00a0D, McCarthy\u00a0O, N\u00f8rgaard\u00a0K. Exercising Safely with the MiniMedTM 780G Automated Insulin Delivery System. Diabetes Technol Ther. 2024;26:84\u201396.","journal-title":"Diabetes Technol Ther"},{"key":"2663_CR9","doi-asserted-by":"crossref","unstructured":"Zimmer RT, Auth A, Schierbauer J, Haupt S, Wachsmuth N, Zimmermann P, et\u00a0al. (Hybrid) Closed-Loop Systems: From Announced to Unannounced Exercise. Diabetes Technol Ther. 2023;.","DOI":"10.1089\/dia.2023.0293"},{"key":"2663_CR10","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s00125-024-06308-z","volume":"68","author":"O Moser","year":"2025","unstructured":"Moser\u00a0O, Zaharieva\u00a0DP, Adolfsson\u00a0P, Battelino\u00a0T, Bracken\u00a0RM, Buckingham\u00a0BA, et\u00a0al. The use of automated insulin delivery around physical activity and exercise in type\u00a01 diabetes: a\u00a0position statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Diabetologia. 2025;68:255\u201380.","journal-title":"Diabetologia"},{"key":"2663_CR11","doi-asserted-by":"crossref","unstructured":"Moser O, Zaharieva D, Adolfsson P, Battelino T, Bracken RM, Buckingham BA, et\u00a0al. The Use of Automated Insulin Delivery around Physical Activity and Exercise in Type\u00a01 Diabetes: A\u00a0Position Statement of the European Association for the Study of Diabetes (EASD) and the International Society for Pediatric and Adolescent Diabetes (ISPAD). Horm Res Paediatr. 2024; 1\u201328.","DOI":"10.1159\/000542287"},{"key":"2663_CR12","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.2337\/dc23-0119","volume":"46","author":"J Garcia-Tirado","year":"2023","unstructured":"Garcia-Tirado\u00a0J, Colmegna\u00a0P, Villard\u00a0O, Diaz\u00a0JL, Esquivel-Zuniga\u00a0R, Koravi\u00a0CLK, et\u00a0al. Assessment of Meal Anticipation for Improving Fully Automated Insulin Delivery in Adults With Type\u00a01 Diabetes. Diabetes Care. 2023;46:1652\u20138.","journal-title":"Diabetes Care"},{"key":"2663_CR13","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1089\/dia.2023.0139","volume":"25","author":"R Shalit","year":"2023","unstructured":"Shalit\u00a0R, Minsky\u00a0N, Laron-Hirsh\u00a0M, Cohen\u00a0O, Kurtz\u00a0N, Roy\u00a0A, et\u00a0al. Unannounced Meal Challenges Using an Advanced Hybrid Closed-Loop System. Diabetes Technol Ther. 2023;25:579\u201388.","journal-title":"Diabetes Technol Ther"},{"key":"2663_CR14","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jcjd.2022.10.006","volume":"47","author":"C Parent","year":"2023","unstructured":"Parent\u00a0C, Lespagnol\u00a0E, Berthoin\u00a0S, Tagougui\u00a0S, Heyman\u00a0J, Stuckens\u00a0C, et\u00a0al. Barriers to Physical Activity in Children and Adults Living With Type\u00a01 Diabetes: A\u00a0Complex Link With Real-life Glycemic Excursions. Can J Diabetes. 2023;47:124\u201332.","journal-title":"Can J Diabetes"},{"key":"2663_CR15","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1089\/dia.2018.0364","volume":"21","author":"DP Zaharieva","year":"2019","unstructured":"Zaharieva\u00a0DP, Turksoy\u00a0K, McGaugh\u00a0SM, Pooni\u00a0R, Vienneau\u00a0T, Ly\u00a0T, et\u00a0al. Lag Time Remains with Newer Real-Time Continuous Glucose Monitoring Technology during Aerobic Exercise in Adults Living with Type\u00a01 Diabetes. Diabetes Technol Ther. 2019;21:313\u201321.","journal-title":"Diabetes Technol Ther"},{"key":"2663_CR16","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1089\/dia.2018.0387","volume":"21","author":"A Li","year":"2019","unstructured":"Li\u00a0A, Riddell\u00a0MC, Potashner\u00a0D, Brown\u00a0RE, Aronson\u00a0R. Time Lag and Accuracy of Continuous Glucose Monitoring During High Intensity Interval Training in Adults with Type\u00a01 Diabetes. Diabetes Technol Ther. 2019;21:286\u201394.","journal-title":"Diabetes Technol Ther"},{"key":"2663_CR17","doi-asserted-by":"crossref","unstructured":"Guillot FH, Jacobs PG, Wilson LM, El Youssef J, Gabo VB, Branigan DL, et\u00a0al. Accuracy of the Dexcom G6 Glucose Sensor during Aerobic, Resistance, and Interval Exercise in Adults with Type\u00a01 Diabetes. Biosens. 2020;10.","DOI":"10.3390\/bios10100138"},{"key":"2663_CR18","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1177\/19322968211023522","volume":"16","author":"G Da Prato","year":"2022","unstructured":"Da Prato\u00a0G, Pasquini\u00a0S, Rinaldi\u00a0E, Lucianer\u00a0T, Don\u00e0\u00a0S, Santi\u00a0L, et\u00a0al. Accuracy of CGM Systems During Continuous and Interval Exercise in Adults with Type\u00a01 Diabetes. J\u00a0Diabetes Sci Technol. 2022;16:1436\u201343.","journal-title":"J Diabetes Sci Technol"},{"key":"2663_CR19","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1111\/dom.14609","volume":"24","author":"O Moser","year":"2022","unstructured":"Moser\u00a0O, Sternad\u00a0C, Eckstein\u00a0ML, Szadkowska\u00a0A, Michalak\u00a0A, Mader\u00a0JK, et\u00a0al. Performance of intermittently scanned continuous glucose monitoring systems in people with type\u00a01 diabetes: A\u00a0pooled analysis. Diabetes Obes Metab. 2022;24:522\u20139.","journal-title":"Diabetes Obes Metab"},{"key":"2663_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3390\/nu8080489","volume":"8","author":"O Moser","year":"2016","unstructured":"Moser\u00a0O, Mader\u00a0J, Tschakert\u00a0G, Mueller\u00a0A, Groeschl\u00a0W, Pieber\u00a0T, et\u00a0al. Accuracy of Continuous Glucose Monitoring (CGM) during Continuous and High-Intensity Interval Exercise in Patients with Type\u00a01 Diabetes Mellitus. Nutrients. 2016;8:489.","journal-title":"Nutrients"},{"key":"2663_CR21","volume-title":"EU-Leitlinien f\u00fcr k\u00f6rperliche Aktivit\u00e4t Empfohlene politische Ma\u00dfnahmen zur Unterst\u00fctzung gesundheitsf\u00f6rdernder k\u00f6rperlicher Bet\u00e4tigung","author":"EU-Arbeitsgruppe \u201eSport & Gesundheit","year":"2008","unstructured":"EU-Arbeitsgruppe \u201eSport & Gesundheit. EU-Leitlinien f\u00fcr k\u00f6rperliche Aktivit\u00e4t Empfohlene politische Ma\u00dfnahmen zur Unterst\u00fctzung gesundheitsf\u00f6rdernder k\u00f6rperlicher Bet\u00e4tigung. 2008."},{"key":"2663_CR22","unstructured":"Nitz, P., Mibs, M., & Hoffmann, V. (2021). Was ist Bewegung? | Stiftung Gesundheitswissen. https:\/\/www.stiftung-gesundheitswissen.de\/wissen\/gesuender-leben-mit-bewegung\/was-ist-bewegung"},{"key":"2663_CR23","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1089\/dia.2022.0338","volume":"25","author":"\u00c9 Myette-Cot\u00e9","year":"2023","unstructured":"Myette-Cot\u00e9 \u00c9, Molveau\u00a0J, Wu\u00a0Z, Raffray\u00a0M, Devaux\u00a0M, Tagougui\u00a0S, et\u00a0al. A\u00a0Randomized Crossover Pilot Study Evaluating Glucose Control During Exercise Initiated 1 or 2\u202fh After a\u00a0Meal in Adults with Type\u00a01 Diabetes Treated with an Automated Insulin Delivery System. Diabetes Technol Ther. 2023;25:122\u201330.","journal-title":"Diabetes Technol Ther"},{"key":"2663_CR24","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1089\/dia.2023.0009","volume":"25","author":"OM McCarthy","year":"2023","unstructured":"McCarthy\u00a0OM, Christensen\u00a0MB, Kristensen\u00a0KB, Schmidt\u00a0S, Ranjan\u00a0AG, Bain\u00a0SC, et\u00a0al. Automated Insulin Delivery Around Exercise in Adults with Type\u00a01 Diabetes: A\u00a0Pilot Randomized Controlled Study. Diabetes Technol Ther. 2023;25:476\u201384.","journal-title":"Diabetes Technol Ther"},{"key":"2663_CR25","doi-asserted-by":"publisher","first-page":"480","DOI":"10.2337\/dc19-1433","volume":"43","author":"MH Lee","year":"2020","unstructured":"Lee\u00a0MH, Vogrin\u00a0S, Paldus\u00a0B, Jayawardene\u00a0D, Jones\u00a0HM, McAuley\u00a0SA, et\u00a0al. Glucose and Counterregulatory Responses to Exercise in Adults With Type\u00a01 Diabetes and Impaired Awareness of Hypoglycemia Using Closed-Loop Insulin Delivery: A\u00a0Randomized Crossover Study. Diabetes Care. 2020;43:480\u20133.","journal-title":"Diabetes Care"},{"key":"2663_CR26","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1007\/s00125-020-05244-y","volume":"63","author":"S Tagougui","year":"2020","unstructured":"Tagougui\u00a0S, Taleb\u00a0N, Legault\u00a0L, Supp\u00e8re\u00a0C, Messier\u00a0V, Boukabous\u00a0I, et\u00a0al. A\u00a0single-blind, randomised, crossover study to reduce hypoglycaemia risk during postprandial exercise with closed-loop insulin delivery in adults with type\u00a01 diabetes: announced (with or without bolus reduction) vs unannounced exercise strategies. Diabetologia. 2020;63:2282\u201391.","journal-title":"Diabetologia"},{"key":"2663_CR27","unstructured":"Moser O, Mueller A, Andritz E, Wurm E, Grothoff A, Froehlich-Reiterer E, et\u00a0al. Performance of Automated Insulin Delivery systems during a\u00a0winter ski camp in children and adolescents with type\u00a01 diabetes: the InSki trial. Diabetologia. 2024;. EASD confe:A-24-1787-EASD."},{"key":"2663_CR28","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.jcjd.2022.11.006","volume":"47","author":"RD McClure","year":"2023","unstructured":"McClure\u00a0RD, Alc\u00e1ntara-Cordero\u00a0FJ, Weseen\u00a0E, Maldaner\u00a0M, Hart\u00a0S, Nitz\u00a0C, et\u00a0al. Systematic Review and Meta-analysis of Blood Glucose Response to High-intensity Interval Exercise in Adults With Type\u00a01 Diabetes. Can J Diabetes. 2023;47:171\u20139.","journal-title":"Can J Diabetes"},{"key":"2663_CR29","doi-asserted-by":"crossref","unstructured":"Bergford S, Riddell MC, Gal RL, Patton SR, Clements MA, Sherr JL, et\u00a0al. Predicting Hypoglycemia and Hyperglycemia Risk During and After Activity for Adolescents with Type\u00a01 Diabetes. Diabetes Technol Ther. 2024;.","DOI":"10.1089\/dia.2024.0061"},{"key":"2663_CR30","doi-asserted-by":"crossref","unstructured":"Moser O, Tschakert G, Mueller A, Groeschl W, Pieber TR, Obermayer-Pietsch B, et\u00a0al. Effects of High-Intensity Interval Exercise versus Moderate Continuous Exercise on Glucose Homeostasis and Hormone Response in Patients with Type\u00a01 Diabetes Mellitus Using Novel Ultra-Long-Acting Insulin. PLoS ONE. 2015;10.","DOI":"10.1371\/journal.pone.0136489"},{"key":"2663_CR31","first-page":"99","volume":"20","author":"MC Riddell","year":"2019","unstructured":"Riddell\u00a0MC, Zaharieva\u00a0DP, Tansey\u00a0M, Tsalikian\u00a0E, Admon\u00a0G, Li\u00a0Z, et\u00a0al. Individual glucose responses to prolonged moderate intensity aerobic exercise in adolescents with type\u00a01 diabetes: The higher they start, the harder they fall. Pediatr Diabetes. 2019;20:99\u2013106.","journal-title":"Pediatr Diabetes"},{"issue":"12","key":"2663_CR32","doi-asserted-by":"publisher","first-page":"2501","DOI":"10.1007\/s00125-020-05263-9","volume":"63","author":"O Moser","year":"2020","unstructured":"Moser\u00a0O, Riddell\u00a0MC, Eckstein\u00a0ML, Adolfsson\u00a0P, Rabasa-Lhoret\u00a0R, van den Boom\u00a0L, et\u00a0al. Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type\u00a01 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Diabetologia. 2020;63(12):2501\u201320. https:\/\/doi.org\/10.1007\/s00125-020-05263-9.","journal-title":"Diabetologia"},{"key":"2663_CR33","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1111\/pedi.13105","volume":"21","author":"O Moser","year":"2020","unstructured":"Moser\u00a0O, Riddell\u00a0MC, Eckstein\u00a0ML, Adolfsson\u00a0P, Rabasa-Lhoret\u00a0R, van den Boom\u00a0L, et\u00a0al. Glucose management for exercise using continuous glucose monitoring (CGM) and intermittently scanned CGM (isCGM) systems in type\u00a01 diabetes: position statement of the European Association for the Study of Diabetes (EASD) and of the International Society for Pediatric and Adolescent Diabetes (ISPAD) endorsed by JDRF and supported by the American Diabetes Association (ADA). Pediatr Diabetes. 2020;21:1375\u201393.","journal-title":"Pediatr Diabetes"},{"key":"2663_CR34","doi-asserted-by":"crossref","unstructured":"Moser O, M\u00fcller A, Aberer F, Aziz F, Kojzar H, Sourij C, et\u00a0al. Comparison of Insulin Glargine 300\u202fU\/mL and Insulin Degludec 100\u202fU\/mL Around Spontaneous Exercise Sessions in Adults with Type\u00a01 Diabetes: A\u00a0Randomized Cross-Over Trial (ULTRAFLEXI-1\u00a0Study). Diabetes Technol Ther. 2023;25.","DOI":"10.1089\/dia.2022.0422"},{"key":"2663_CR35","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1210\/js.2017-00389","volume":"1","author":"LM Laffel","year":"2017","unstructured":"Laffel\u00a0LM, Aleppo\u00a0G, Buckingham\u00a0BA, Forlenza\u00a0GP, Rasbach\u00a0LE, Tsalikian\u00a0E, et\u00a0al. A\u00a0Practical Approach to Using Trend Arrows on the Dexcom G5 CGM System to Manage Children and Adolescents With Diabetes. J\u00a0Endocr Soc. 2017;1:1461.","journal-title":"J Endocr Soc"},{"key":"2663_CR36","doi-asserted-by":"crossref","unstructured":"Moser O, Eckstein ML, Mueller A, Birnbaumer P, Aberer F, Koehler G, et\u00a0al. Pre-Exercise Blood Glucose Levels Determine the Amount of Orally Administered Carbohydrates during Physical Exercise in Individuals with Type\u00a01 Diabetes\u2014A Randomized Cross-Over Trial. Nutrients. 2019;11.","DOI":"10.3390\/nu11061287"},{"key":"2663_CR37","doi-asserted-by":"publisher","first-page":"194","DOI":"10.2337\/dc21-1593","volume":"45","author":"B Paldus","year":"2022","unstructured":"Paldus\u00a0B, Morrison\u00a0D, Zaharieva\u00a0DP, Lee\u00a0MH, Jones\u00a0H, Obeyesekere\u00a0V, et\u00a0al. A\u00a0Randomized Crossover Trial Comparing Glucose Control During Moderate-Intensity, High-Intensity, and Resistance Exercise With Hybrid Closed-Loop Insulin Delivery While Profiling Potential Additional Signals in Adults With Type\u00a01 Diabetes. Diabetes Care. 2022;45:194\u2013203.","journal-title":"Diabetes Care"},{"key":"2663_CR38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1089\/dia.2021.0221","volume":"24","author":"D Morrison","year":"2022","unstructured":"Morrison\u00a0D, Zaharieva\u00a0DP, Lee\u00a0MH, Paldus\u00a0B, Vogrin\u00a0S, Grosman\u00a0B, et\u00a0al. Comparable Glucose Control with Fast-Acting Insulin Aspart Versus Insulin Aspart Using a\u00a0Second-Generation Hybrid Closed-Loop System During Exercise. Diabetes Technol Ther. 2022;24:93\u2013101.","journal-title":"Diabetes Technol Ther"},{"issue":"17","key":"2663_CR39","doi-asserted-by":"publisher","first-page":"P04","DOI":"10.1055\/s-0044-1785312","volume":"19","author":"O Moser","year":"2024","unstructured":"Moser\u00a0O, Sanfilippo\u00a0S, Grothoff\u00a0A, Hoffmann\u00a0S, Wachsmuth\u00a0N, Voit\u00a0T, et\u00a0al. Sicherheit und Effizienz des mylife CamAPS FX Hybrid Closed-Loop Systems w\u00e4hrend maximaler Ausbelastungstests bei Kindern und Jugendlichen mit Diabetes Mellitus Typ\u00a01: eine explorative pr\u00e4limin\u00e4re Analyse der InLoopChild Studie. Diabetol Stoffwechs. 2024;19(17):P4\u20135. https:\/\/doi.org\/10.1055\/s-0044-1785312.","journal-title":"Diabetol Stoffwechs"},{"key":"2663_CR40","doi-asserted-by":"crossref","unstructured":"Moser O, Sanfilippo S, Grothoff A, Hoffmann S, Wachsmuth N, Voit T, et\u00a0al. Sicherheit und Effizienz des mylife CamAPS FX Hybrid Closed-Loop Systems w\u00e4hrend maximaler Ausbelastungstests bei Kindern und Jugendlichen mit Diabetes Mellitus Typ\u00a01: eine explorative pr\u00e4limin\u00e4re Analyse der InLoopChild Studie. Diabetolgie. 2024; P4\u2013P5.","DOI":"10.1055\/s-0045-1807544"},{"key":"2663_CR41","doi-asserted-by":"crossref","unstructured":"Fushimi E, Aiello EM, Cho S, Riddell MC, Gal R, Martin C, et\u00a0al. Online classification of unstructured free-living exercise sessions in people with Type\u00a01 Diabetes. Diabetes Technol Ther. 2024;.","DOI":"10.1089\/dia.2023.0528"},{"key":"2663_CR42","doi-asserted-by":"crossref","unstructured":"Zaharieva DP, Messer LH, Paldus B, O\u2019Neal DN, Maahs DM, Riddell MC. Glucose Control During Physical Activity and Exercise Using Closed Loop Technology in Adults and Adolescents with Type\u00a01 Diabetes. Can J Diabetes Elsevier Bv. 2020; 740\u20139.","DOI":"10.1016\/j.jcjd.2020.06.003"},{"key":"2663_CR43","doi-asserted-by":"crossref","unstructured":"Mattsson S, Jendle J, Adolfsson P. Carbohydrate Loading Followed by High Carbohydrate Intake During Prolonged Physical Exercise and Its Impact on Glucose Control in Individuals With Diabetes Type\u00a01\u2014An Exploratory Study. Front Endocrinol. 2019;10.","DOI":"10.3389\/fendo.2019.00571"},{"key":"2663_CR44","doi-asserted-by":"publisher","first-page":"2170","DOI":"10.1111\/dom.14442","volume":"23","author":"S Franc","year":"2021","unstructured":"Franc\u00a0S, Benhamou\u00a0PY, Borot\u00a0S, Chaillous\u00a0L, Delemer\u00a0B, Doron\u00a0M, et\u00a0al. No more hypoglycaemia on days with physical activity and unrestricted diet when using a\u00a0closed-loop system for 12\u00a0weeks: A\u00a0post hoc secondary analysis of the multicentre, randomized controlled Diabeloop WP7 trial. Diabetes Obes Metab. 2021;23:2170\u20136.","journal-title":"Diabetes Obes Metab"},{"key":"2663_CR45","doi-asserted-by":"publisher","first-page":"168","DOI":"10.2337\/cd21-0083","volume":"40","author":"C Berget","year":"2022","unstructured":"Berget\u00a0C, Sherr\u00a0JL, DeSalvo\u00a0DJ, Kingman\u00a0RS, Stone\u00a0SL, Brown\u00a0SA, et\u00a0al. Clinical Implementation of the Omnipod 5 Automated Insulin Delivery System: Key Considerations for Training and Onboarding People With Diabetes. Clin Diabetes. 2022;40:168\u201384.","journal-title":"Clin Diabetes"},{"key":"2663_CR46","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.2337\/dc23-0470","volume":"46","author":"MS Hughes","year":"2023","unstructured":"Hughes\u00a0MS, Kingman\u00a0RS, Hsu\u00a0L, Lal\u00a0RA, Buckingham\u00a0BA, Zaharieva\u00a0DP. Swimming With the Omnipod 5 Automated Insulin Delivery System: Connectivity in the Water. Diabetes Care. 2023;46:e148\u201350.","journal-title":"Diabetes Care"},{"key":"2663_CR47","unstructured":"Turner LV, Sherr J, Zaharieva DP, Baran JD, Bode BW, Brown SA, Bzdick S, Church MM, Hansen DW, Kingman RS, Laffel L, Shah VN, Stone SL, Vienneau TE, Huyett LM, Dumais B, Ly TT, Riddell MC, Turner LV, Sherr J, Zaharieva DPRM. Activity feature attenuates drop in glucose for individuals with type\u00a01 diabetes using Omnipod\u00ae 5 Automated Insulin Delivery System. ADA Abstr."},{"key":"2663_CR48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1089\/dia.2022.0542","volume":"25","author":"OM McCarthy","year":"2023","unstructured":"McCarthy\u00a0OM, Christensen\u00a0MB, Kristensen\u00a0KB, Schmidt\u00a0S, Ranjan\u00a0AG, Bain\u00a0SC, et\u00a0al. Glycemia Around Exercise in Adults with Type\u00a01 Diabetes Using Automated and Nonautomated Insulin Delivery Pumps: A\u00a0Switch Pilot Trial. Diabetes Technol Ther. 2023;25:287\u201392.","journal-title":"Diabetes Technol Ther"},{"key":"2663_CR49","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1089\/dia.2023.0178","volume":"25","author":"K Dovc","year":"2023","unstructured":"Dovc\u00a0K, Bergford\u00a0S, Fr\u00f6hlich-Reiterer\u00a0E, Zaharieva\u00a0DP, Potocnik\u00a0N, M\u00fcller\u00a0A, et\u00a0al. A\u00a0Comparison of Faster Insulin Aspart with Standard Insulin Aspart Using Hybrid Automated Insulin Delivery System in Active Children and Adolescents with Type\u00a01 Diabetes: A\u00a0Randomized Double-Blind Crossover Trial. Diabetes Technol Ther. 2023;25:612\u201321.","journal-title":"Diabetes Technol Ther"},{"key":"2663_CR50","doi-asserted-by":"crossref","unstructured":"Jayawardene DC, McAuley SA, Horsburgh JC, La Gerche A, Jenkins AJ, Ward GM, et\u00a0al. Closed-Loop Insulin Delivery for Adults with Type\u00a01 Diabetes Undertaking High-Intensity Interval Exercise Versus Moderate-Intensity Exercise: A\u00a0Randomized, Crossover Study. 2017;19:340\u20138. https:\/\/home.liebertpub.com\/dia.","DOI":"10.1089\/dia.2016.0461"},{"key":"2663_CR51","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1111\/dom.12552","volume":"17","author":"S Franc","year":"2015","unstructured":"Franc\u00a0S, Daoudi\u00a0A, Pochat\u00a0A, Petit\u00a0MH, Randazzo\u00a0C, Petit\u00a0C, et\u00a0al. Insulin-based strategies to prevent hypoglycaemia during and after exercise in adult patients with type\u00a01 diabetes on pump therapy: the DIABRASPORT randomized study. Diabetes Obes Metab. 2015;17:1150\u20137.","journal-title":"Diabetes Obes Metab"},{"key":"2663_CR52","doi-asserted-by":"publisher","first-page":"704","DOI":"10.2337\/dc22-1721","volume":"46","author":"MC Riddell","year":"2023","unstructured":"Riddell\u00a0MC, Li\u00a0Z, Gal\u00a0RL, Calhoun\u00a0P, Jacobs\u00a0PG, Clements\u00a0MA, et\u00a0al. Examining the Acute Glycemic Effects of Different Types of Structured Exercise Sessions in Type\u00a01 Diabetes in a\u00a0Real-World Setting: The Type\u00a01 Diabetes and Exercise Initiative (T1DEXI). Diabetes Care. 2023;46:704\u201313.","journal-title":"Diabetes Care"},{"key":"2663_CR53","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1007\/s13300-023-01486-2","volume":"15","author":"A Chico","year":"2024","unstructured":"Chico\u00a0A, Moreno-Fern\u00e1ndez\u00a0J, Fern\u00e1ndez-Garc\u00eda\u00a0D, Sol\u00e1\u00a0E. The Hybrid Closed-Loop System Tandem t:slim X2TM with Control-IQ Technology: Expert Recommendations for Better Management and Optimization. Diabetes Ther. 2024;15:281\u201395.","journal-title":"Diabetes Ther"},{"key":"2663_CR54","unstructured":"Adolfsson P. Automated Insulin Delivery Systems in Pediatric Type\u00a01 Diabetes: A\u00a0Narrative Review. ."},{"key":"2663_CR55","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1089\/dia.2019.0471","volume":"22","author":"MJ Schoelwer","year":"2020","unstructured":"Schoelwer\u00a0MJ, Robic\u00a0JL, Gautier\u00a0T, Fabris\u00a0C, Carr\u00a0K, Clancy-Oliveri\u00a0M, et\u00a0al. Safety and Efficacy of Initializing the Control-IQ Artificial Pancreas System Based on Total Daily Insulin in Adolescents with Type\u00a01 Diabetes. Diabetes Technol Ther. 2020;22:594\u2013601.","journal-title":"Diabetes Technol Ther"},{"key":"2663_CR56","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.2337\/dc17-0883","volume":"40","author":"MD Breton","year":"2017","unstructured":"Breton\u00a0MD, Cher\u00f1avvsky\u00a0DR, Forlenza\u00a0GP, DeBoer\u00a0MD, Robic\u00a0J, Wadwa\u00a0RP, et\u00a0al. Closed-Loop Control During Intense Prolonged Outdoor Exercise in Adolescents With Type\u00a01 Diabetes: The Artificial Pancreas Ski Study. Diabetes Care. 2017;40:1644\u201350.","journal-title":"Diabetes Care"},{"key":"2663_CR57","first-page":"759","volume":"20","author":"L Ekhlaspour","year":"2019","unstructured":"Ekhlaspour\u00a0L, Forlenza\u00a0GP, Chernavvsky\u00a0D, Maahs\u00a0DM, Wadwa\u00a0RP, Deboer\u00a0MD, et\u00a0al. Closed loop control in adolescents and children during winter sports: Use of the Tandem Control-IQ AP system. Pediatr Diabetes. 2019;20:759\u201368.","journal-title":"Pediatr Diabetes"},{"key":"2663_CR58","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1089\/dia.2023.0324","volume":"26","author":"C Mameli","year":"2024","unstructured":"Mameli\u00a0C, Rigamonti\u00a0A, Felappi\u00a0B, Nicolucci\u00a0A, Lucisano\u00a0G, Baresi\u00a0S, et\u00a0al. Performance of Tandem Control IQ During Outdoor Physical Activity in Children and Adolescents with Type\u00a01 Diabetes. Diabetes Technol Ther. 2024;26:112\u20138.","journal-title":"Diabetes Technol Ther"}],"container-title":["Wiener klinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02663-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00508-025-02663-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00508-025-02663-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:12:32Z","timestamp":1779315152000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00508-025-02663-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,30]]},"references-count":58,"journal-issue":{"issue":"S4","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2663"],"URL":"https:\/\/doi.org\/10.1007\/s00508-025-02663-y","relation":{},"ISSN":["0043-5325","1613-7671"],"issn-type":[{"value":"0043-5325","type":"print"},{"value":"1613-7671","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,30]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"O.\u00a0Moser gibt folgende Offenlegungen an: Unterst\u00fctzung f\u00fcr klinische Studien erfolgte durch die S\u00ear Cymru\u00a0II COFUND Fellowship\/Europ\u00e4ische Union, Novo Nordisk A\/S, Novo Nordisk AT, Abbott Diabetes Care, Sanofi, Dexcom, Team Novo Nordisk, SAIL, Maisel\u2019s Brauerei, Medtronic AT, EFSD\/EASD, Falke, BISp, perfood, Ypsomed sowie Sinocare. Vortragshonorare wurden von Medtronic AT, Medtronic International, Eli Lilly, Novo Nordisk, Sanofi, TAD Pharma, ADA, Diatec, dem Berufsverband Deutscher Internist*innen, Dexcom, AstraZeneca, Ypsomed, Insulet, der Arbeitsgemeinschaft der Diabetologen in Hessen sowie Abbott erhalten. Reisekostenunterst\u00fctzung f\u00fcr Kongressteilnahmen wurde durch Novo Nordisk A\/S, Novo Nordisk AT, Novo Nordisk UK, Medtronic AT, Sanofi, EASD, \u00d6DG und DDG gew\u00e4hrt. Mitgliedschaften in wissenschaftlichen Beir\u00e4ten bestehen bei Sanofi, TAD Pharma, Dexcom, perfood sowie Medtronic. U.\u00a0Becker gibt folgende Offenlegungen an: Honorare f\u00fcr Vortr\u00e4ge von AstraZeneca, Boehringer Ingelheim und Berlin-Chemie; Kongressteilnahme und Reisekostenunterst\u00fctzung: AstraZeneca. L.\u00a0van den Boom gibt folgende Offenlegungen an: Honorare f\u00fcr Vortr\u00e4ge erhalten von Medtronic, Insulet, Dexcom, Sanofi, E.\u00a0Lilly. C.\u00a0Brinkmann gibt folgende Offenlegungen an: Honorare f\u00fcr Vortr\u00e4ge von E.\u00a0Lilly, Abbott Diabetes Care und Novo Nordisk. Forschungsunterst\u00fctzung durch Abbott Diabetes Care. Mitglied im Beraterboard bei Abbott Diabetes Care. T.\u00a0Danne gibt folgende Offenlegungen an: Er ist der Chief Medical Officer von Breakthrough T1D und hat erkl\u00e4rt, dass diese Institution Zahlungen oder Honorare von AstraZeneca, Abbott, Biomedia, Bayer, Boehringer Ingelheim, Dexcom, Eli Lilly, Insulet, Medtronic, Menarini, Novo Nordisk, Roche, Sanofi, Vitalaire und Ypsomed erhalten hat. T.\u202fD. hat an einem Data Safety Monitoring Board oder Advisory Board f\u00fcr Medtronic und Eli Lilly teilgenommen und erkl\u00e4rt, dass er der Mitbegr\u00fcnder von DreaMed Ltd. ist. E.\u00a0Fr\u00f6hlich-Reiterer gibt folgende Offenlegungen an: Forschungsunterst\u00fctzung und Honorare f\u00fcr Vortr\u00e4ge von Sanofi, E.\u00a0Lilly, Medtronic, Merck, Sandoz. B.\u00a0Gehr gibt folgende Offenlegungen an: Vortrags- und Beratungshonorare von Abbott, Ascensia, Dexcom, Diabeloop, IME-DC, Insulet, Lilly, Novartis, Novo Nordisk, Medtronic, Roche, Vitalaire. A.-T.\u00a0Kietaibl gibt folgende Offenlegungen an: Honorare von Sanofi Aventis GmbH und Roche Diabetes Care Austria GmbH erhalten. Kongressunterst\u00fctzung durch Novo Nordisk, Eli Lilly, GmbH, Boehringer Ingelheim und \u00d6DG. G.\u00a0Koehler gibt folgende Offenlegungen an: Honorare f\u00fcr Vortr\u00e4ge, Advisory Boards oder Reisekostenunterst\u00fctzung von: Amgen, AstraZeneca, Boehringer Ingelheim, Daiichi Sankyo, Eli Lilly, Novo Nordisk AT, Dexcom, Roche, Sanofi Aventis, Austro Control. S.\u00a0Kress gibt folgende Offenlegungen an: Honorare f\u00fcr Vortr\u00e4ge erhalten von Abbott, AstraZeneca, Bayer Vital, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk, Sanofi. J.K.\u00a0Mader gibt folgende Offenlegungen an: Advisory Boards von Abbott Diabetes Care, Becton Dickinson, Biomea Fusion, Dexcom, Eli Lilly, Embecta, Insulet, Medtronic, myLife, Novo Nordisk A\/S, Pharmasens, Roche Diabetes Care, Sanofi-Aventis, Tandem und Viatris; Honorare f\u00fcr Vortragst\u00e4tigkeit: A.\u00a0Menarini Diagnostics, Abbott Diabetes Care, Dexcom, Eli Lilly, Medtrust, MSD, Novo Nordisk A\/S, Roche Diabetes Care, Sanofi, Viatris und Ypsomed. Gesellschafterin: decide Clinical Software GmbH und elyte Diagnostics. B.\u00a0Rami-Merhar gibt folgende Offenlegungen an: Honorare f\u00fcr Vortr\u00e4ge oder Advisory Boards erhalten von Eli Lilly, Sanofi, Medtronic, Abbott Diabetes Care, Insulet. D.\u00a0Pesta gibt an, keine Offenlegungen zu haben. S.\u00a0Sanfilippo gibt folgende Offenlegungen an: Unterst\u00fctzung der Promotion durch ein Promotionsstipendium der Studienstiftung des deutschen Volkes. Unterst\u00fctzung f\u00fcr klinische Studien erfolgte durch Ypsomed. Reisekostenunterst\u00fctzung f\u00fcr Kongressteilnahmen wurde von Ypsomed gew\u00e4hrt. I.\u00a0Sch\u00fctz-Fuhrmann gibt folgende Offenlegungen an: Honorare f\u00fcr Vortragst\u00e4tigkeit: Abbott Diabetes Care, Roche Diabetes Care, Dexcom. H.\u00a0Sourij gibt folgende Offenlegungen an: Advisory Boards von Amgen, Amarin, Boehringer Ingelheim, Bayer, Eli Lilly, Daiichi Sankyo, Novartis, Novo Nordisk, Sanofi-Aventis; Honorare f\u00fcr Vortragst\u00e4tigkeit: Amgen, Amarin, Boehringer Ingelheim, Bayer, Eli Lilly, Daiichi Sankyo, Novartis, Novo Nordisk, Sanofi-Aventis. M.\u00a0Tauschmann gibt folgende Offenlegungen an: Vortragshonorare von Medtronic AT, Eli Lilly, Sanofi, Diatec und Ypsomed erhalten zu haben. Reisekostenunterst\u00fctzung f\u00fcr Kongressteilnahmen wurde durch KelCon GmbH, Ypsomed und \u00d6DG gew\u00e4hrt. Mitgliedschaften in wissenschaftlichen Beir\u00e4ten bestehen bei Sanofi, Abbott. U.\u00a0Thurm gibt folgende Offenlegungen an: Vortragshonorare von Abbott, AstraZeneca, Dexcom, Diashop, Glooko, Lilly Deutschland, Medtrix Verlag, Medtronic, Novo Nordisk, Roche Diabetes Care, Ypsomed, Sanofi-Aventis. G.\u00a0Treiber gibt folgende Offenlegungen an: Honorare f\u00fcr Vortr\u00e4ge und Reisekostenunterst\u00fctzung f\u00fcr Kongressteilnahme erhalten von Medtronic AT, Sanofi, E.\u00a0Lilly, Novo Nordisk, Bayer Austria, \u00d6DG, \u00d6sterreichische Akademie der \u00c4rzte. S.\u00a0Hofer gibt folgende Offenlegungen an: Forschungsunterst\u00fctzung und Honorare f\u00fcr Vortr\u00e4ge erhalten von Ypsomed, Sanofi, E.\u00a0Lilly.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}